On Peptides, FDA Staff Scientists At Odds With Advisory Panel

An FDA advisory committee voted to allow compounding for six of seven peptides it reviewed.

FDA staff scientists warned there is limited evidence on safety, effectiveness, and manufacturing quality.

If finalized, the decision could expand access to unapproved peptide treatments through specialty pharmacies.

BPC-157 drew attention because it is popular in wellness circles but has little human data and possible cancer concerns.